Mirtazapina Bluefish (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also blocks certain serotonin receptors (5‑HT2, 5‑HT3) while stimulating 5‑HT1A receptors, resulting in enhanced neurotransmission that improves mood and anxiety.

The appropriate dose of Mirtazapina Bluefish is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to clinical judgment and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and discuss alternative options when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined antagonism of α2‑adrenergic and specific serotonin receptors. This profile often results in pronounced sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about these side effects.

Mirtazapina Bluefish should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct light, and ensure they are out of reach of children.

The medication is taken orally, usually once daily in the evening, as directed by the prescribing clinician. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include rare blood disorders such as agranulocytosis, severe allergic reactions like anaphylaxis or Stevens‑Johnson syndrome, and potential liver injury. Patients should be monitored for signs of infection, rash, or jaundice, and seek immediate medical attention if these occur.

Mirtazapine is contraindicated in individuals who have a known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients using monoamine oxidase inhibitors, those with severe hepatic or renal impairment, and patients at risk of significant sedation or orthostatic hypotension.